Michael McCaughan
If you think this is a bad time to try to get a loan, try selling a type 2 diabetes...
Welcome to In Vivo
Create an account to read this article
Already a subscriber?
Regulatory Risk and Business Development: Type 2 Diabetes Falls Out of Favor
If you think this is a bad time to try to get a loan, try selling a type 2 diabetes research project to a Big Pharma company. Diabetes, simultaneously one of the largest yet most under-treated prescription drug markets in the world, is suddenly out of favor with Big Pharma business development executives. And the reason isn't hard to spot: the belief that regulatory hurdles have fundamentally changed the business case for drug development in the category.
More from Archive
• By
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
• By
Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.
• By
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.
Sponsored by:
The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.
More from In Vivo
• By
Facing rising costs and tighter regulations, PBMs and insurers are accelerating the shift to value-based drug coverage, demanding stronger proof of therapeutic and economic benefit from pharma.
• By
Akelos is developing a first-in-class, non-addictive HCN1 inhibitor for peripheral neuropathic pain, based on anesthesiology research from Weill Cornell. The compound is designed to avoid the brain and heart, and has shown strong preclinical efficacy and safety with NIH backed development underway.
• By
As gene therapy advances and regulations tighten, biopharma companies face growing pressure to design diagnostic assays that are both flexible and future ready. Strategic early investment in assay development can prevent costly delays and rework as therapies progress toward approval.